Azvudine

Generic Name
Azvudine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C9H11FN6O4
CAS Number
1011529-10-4
Unique Ingredient Identifier
IJ2XP0ID0K
Background

Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

Indication

⑴用于与核苷逆转录酶抑制剂及非核苷逆转录酶抑制剂联用，治疗高病毒载量的成年HIV-1感染患者。

⑵用于治疗普通型新型冠状病毒肺炎（COVID-19）成年患者。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

Completed
Conditions
COVID-19
Azvudine
Interventions
Drug: Azvudine
Drug: Paxlovid
First Posted Date
2024-04-05
Last Posted Date
2024-04-05
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Target Recruit Count
32864
Registration Number
NCT06349655
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Active, not recruiting
Conditions
COVID-19
Interventions
Drug: Azvudine
First Posted Date
2023-08-23
Last Posted Date
2023-09-21
Lead Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
4201
Registration Number
NCT06006611
Locations
🇨🇳

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

Phase 4
Recruiting
Conditions
COVID-19
Interventions
Drug: Azvudine
Drug: Nirmatrelvir-Ritonavir
First Posted Date
2023-01-25
Last Posted Date
2023-02-27
Lead Sponsor
Shandong Provincial Hospital
Target Recruit Count
410
Registration Number
NCT05697055
Locations
🇨🇳

Shandong Provincial Hospital, Jinan, Shandong, China

Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness

Phase 2
Recruiting
Conditions
COVID-19 Respiratory Infection
Interventions
Drug: Placebo
Drug: Azvudine
First Posted Date
2023-01-18
Last Posted Date
2024-11-25
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
1096
Registration Number
NCT05689034
Locations
🇨🇳

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China

Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China

Phase 2
Recruiting
Conditions
COVID-19
Interventions
Drug: Azvudine
Drug: Placebo
First Posted Date
2023-01-12
Last Posted Date
2023-01-31
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
300
Registration Number
NCT05682599
Locations
🇨🇳

Huashan Hospital, Shanghai, Shanghai, China

Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients

Not yet recruiting
Conditions
COVID-19
First Posted Date
2023-01-09
Last Posted Date
2023-01-13
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
400
Registration Number
NCT05675748

The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

Not Applicable
Recruiting
Conditions
SARS-CoV-2 Infection
Interventions
Drug: Paxlovid group
Drug: Azvudine
First Posted Date
2022-12-08
Last Posted Date
2022-12-08
Lead Sponsor
Southeast University, China
Target Recruit Count
540
Registration Number
NCT05642910
Locations
🇨🇳

Hohhot First Hospital, Hohhot, Inner Mongolia, China

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

Phase 2
Recruiting
Conditions
SARS-CoV-2 Infection
Interventions
Drug: Azvudine
Drug: Placebo
First Posted Date
2022-12-01
Last Posted Date
2023-01-09
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
1550
Registration Number
NCT05633433
Locations
🇵🇭

Cebu Doctors' University Hospitol, Cebu City, Philippines

🇵🇭

University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines

🇲🇾

International Islamic University Malaysia, Kuantan, Malaysia

and more 7 locations

An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia

Recruiting
Conditions
COVID-19 Respiratory Infection
Interventions
Drug: Azvudine
First Posted Date
2022-11-18
Last Posted Date
2023-10-03
Lead Sponsor
Qianfoshan Hospital
Target Recruit Count
500
Registration Number
NCT05621993
Locations
🇨🇳

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong, China

Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

Phase 3
Completed
Conditions
COVID-19
Interventions
Drug: AZVUDINE placebo
Drug: AZVUDINE
First Posted Date
2021-09-02
Last Posted Date
2022-08-12
Lead Sponsor
HRH Pharmaceuticals Limited
Target Recruit Count
312
Registration Number
NCT05033145
Locations
🇧🇷

Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute, Campos Dos Goytacazes, Rio De Janeiro, Brazil

🇧🇷

Hospital Moacyr Gomes de Azevedo, Cambuci, RJ, Brazil

🇧🇷

Hospital Santa Casa de Misericórdia de Campos, Campos Dos Goytacazes, RJ, Brazil

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy